MX2011011825A - Anticuerpos humanizados para axl. - Google Patents

Anticuerpos humanizados para axl.

Info

Publication number
MX2011011825A
MX2011011825A MX2011011825A MX2011011825A MX2011011825A MX 2011011825 A MX2011011825 A MX 2011011825A MX 2011011825 A MX2011011825 A MX 2011011825A MX 2011011825 A MX2011011825 A MX 2011011825A MX 2011011825 A MX2011011825 A MX 2011011825A
Authority
MX
Mexico
Prior art keywords
axl antibodies
humanized
humanized axl
axl
bind
Prior art date
Application number
MX2011011825A
Other languages
English (en)
Spanish (es)
Inventor
Peter Wirtz
Takeshi Takizawa
Jens Ruhe
Tomoko Takayama
Original Assignee
U3 Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09006355A external-priority patent/EP2270053A1/en
Application filed by U3 Pharma Gmbh filed Critical U3 Pharma Gmbh
Publication of MX2011011825A publication Critical patent/MX2011011825A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2011011825A 2009-05-11 2010-05-11 Anticuerpos humanizados para axl. MX2011011825A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09006355A EP2270053A1 (en) 2009-05-11 2009-05-11 Humanized AXL antibodies
EP09006474 2009-05-13
PCT/EP2010/056487 WO2010130751A1 (en) 2009-05-11 2010-05-11 Humanized axl antibodies

Publications (1)

Publication Number Publication Date
MX2011011825A true MX2011011825A (es) 2011-12-06

Family

ID=42272537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011825A MX2011011825A (es) 2009-05-11 2010-05-11 Anticuerpos humanizados para axl.

Country Status (15)

Country Link
US (2) US8841424B2 (enExample)
EP (1) EP2430050A1 (enExample)
JP (2) JP5909442B2 (enExample)
KR (1) KR20120035145A (enExample)
CN (1) CN102421802B (enExample)
AR (1) AR076564A1 (enExample)
AU (1) AU2010247464B2 (enExample)
BR (1) BRPI1013428A2 (enExample)
CA (1) CA2759836A1 (enExample)
IL (1) IL216147A (enExample)
MX (1) MX2011011825A (enExample)
RU (2) RU2571224C2 (enExample)
TW (2) TW201105348A (enExample)
WO (1) WO2010130751A1 (enExample)
ZA (1) ZA201107529B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120035145A (ko) * 2009-05-11 2012-04-13 우드라이 파마 게엠베하 인간화 ａｘｌ 항체
WO2011041721A1 (en) 2009-10-02 2011-04-07 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
EP3388443A1 (en) 2011-05-13 2018-10-17 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
AU2012273955A1 (en) * 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
WO2012175691A1 (en) * 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
CN104955842B (zh) * 2012-11-05 2018-04-10 皮埃尔法布雷医药公司 抗原结合蛋白及其作为定位产品用于治疗癌症的用途
FI2931265T6 (fi) 2012-12-14 2023-05-23 Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa
ES2764299T3 (es) * 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
JP6931609B2 (ja) 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
JP6913030B2 (ja) * 2015-05-18 2021-08-04 アジェンシス，インコーポレイテッド Ａｘｌタンパク質に結合する抗体
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
LT3319993T (lt) 2015-07-10 2020-05-11 Genmab A/S Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
JP6878283B2 (ja) 2015-09-24 2021-05-26 第一三共株式会社 抗ｇａｒｐ抗体
WO2017180842A1 (en) 2016-04-15 2017-10-19 Bioatla, Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109160941B (zh) * 2018-09-29 2020-09-04 未名生物医药有限公司 蛋白序列17e11及其用途
RU2678569C1 (ru) * 2018-10-31 2019-01-30 Гордейчук Владимир Евгеньевич Способ подавления метастазирования опухолей
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
JP2023521753A (ja) 2020-04-08 2023-05-25 ベルゲンビオ アーエスアー 抗ウイルス療法
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
EP4286406A4 (en) 2021-01-29 2025-07-23 Illimis Therapeutics Inc FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN115927243A (zh) * 2022-09-13 2023-04-07 中山大学 一种akt1蛋白的抑制性磷酸化位点及其应用
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
EP0939653B1 (en) * 1996-03-20 2005-08-31 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
WO2000075333A1 (en) 1999-06-07 2000-12-14 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US7910100B2 (en) 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
DK1865986T3 (en) 2005-03-08 2016-04-11 Pfizer Prod Inc The anti-CTLA-4 antibody compositions
WO2006105062A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
ES2424042T3 (es) * 2005-06-07 2013-09-26 Esbatech - A Novartis Company Llc Anticuerpos estables y solubles que inhiben TNF±
CA2692320A1 (en) 2007-07-02 2009-01-08 Wyeth Methods of treating bone disorders with modulators of axl
WO2010008411A1 (en) * 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
EP2220121B1 (en) * 2007-11-12 2015-08-19 U3 Pharma GmbH Axl antibodies
KR20120035145A (ko) * 2009-05-11 2012-04-13 우드라이 파마 게엠베하 인간화 ａｘｌ 항체

Also Published As

Publication number Publication date
ZA201107529B (en) 2012-06-27
RU2571224C2 (ru) 2015-12-20
US8841424B2 (en) 2014-09-23
BRPI1013428A2 (pt) 2019-07-02
IL216147A (en) 2016-04-21
IL216147A0 (en) 2012-01-31
EP2430050A1 (en) 2012-03-21
JP2012526530A (ja) 2012-11-01
CN102421802B (zh) 2014-08-20
KR20120035145A (ko) 2012-04-13
WO2010130751A1 (en) 2010-11-18
TW201105348A (en) 2011-02-16
US20150037323A1 (en) 2015-02-05
CN102421802A (zh) 2012-04-18
US20120117670A1 (en) 2012-05-10
JP2016011306A (ja) 2016-01-21
AU2010247464B2 (en) 2014-09-11
AU2010247464A1 (en) 2011-11-10
TWI526223B (zh) 2016-03-21
RU2011150183A (ru) 2013-06-20
CA2759836A1 (en) 2010-11-18
TW201509431A (zh) 2015-03-16
RU2015147287A (ru) 2017-05-12
JP5909442B2 (ja) 2016-04-26
AR076564A1 (es) 2011-06-22

Similar Documents

Publication Publication Date Title
MX2011011825A (es) Anticuerpos humanizados para axl.
MX2010005031A (es) Anticuerpos de axl.
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
PH12013501096B1 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
MX2012006553A (es) Anticuerpos contra csf-1r humano y usos de los mismos.
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
IN2012DN00863A (enExample)
GB201017345D0 (en) Receptor antagonists
PH12017500864A1 (en) Anti-notch1 antibodies
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
TN2011000639A1 (en) Compounds which selectively modulate the cb2 receptor
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
TN2011000673A1 (en) Bace inhibitors
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
UA111818C2 (uk) Антитіло проти csf-1r
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
TW201144300A (en) Tetrazole compounds which selectively modulate the CB2 receptor
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
MX2011008458A (es) Metodos para preparar agonistas y antagonistas del receptor s1p.
UA33402U (ru) Использование антагониста рецепторов интерлейкина-1 в качестве средства с антигипоксическим действием

Legal Events

Date Code Title Description
FG Grant or registration